ArticleQuantitative imaging in medicine and surgery2026
Ultrasound-guided transverse myofascial acupotomy for the tibialis posterior muscle in type II painful accessory navicular: a retrospective cohort study with 1-year follow-up.
Article in Quantitative imaging in medicine and surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Type II painful accessory navicular (PAN II) commonly causes medial foot pain and functional limitation, and symptoms may persist when conservative care fails to reduce posterior tibial tendon traction on the accessory navicular synchondrosis. This study evaluated whether Ultrasound-Guided Transverse Myofascial Acupotomy for Tibialis Posterior (UG-MA-TP) is associated with better 1-year clinical and biomechanical outcomes than conventional conservative therapy. Methods: This retrospective cohort study included 70 patients with PAN II treated between February 2022 and May 2024 at a single tertiary center. Patients were stratified according to treatment modality into the UG-MA-TP group (n=35) and the conventional therapy group (n=35). Outcomes included the 12-month clinical response rate and magnetic resonance imaging (MRI)-defined bone marrow edema resolution, serial Visual Analog Scale (VAS) pain scores and tibialis posterior/medial gastrocnemius muscle tone, American Orthopaedic Foot & Ankle Society (AOFAS) midfoot scores, surface electromyography-derived normalized root mean square relative values (nRMS-RV), Meary's angle, and adverse events. Results: The UG-MA-TP group showed significant improvements in VAS and AOFAS scores and a sustained reduction in tibialis posterior muscle tone after intervention (all P<0.05). In contrast, the control group showed transient improvement only at 1 month, followed by a return toward baseline. At 12 months, the UG-MA-TP group had a higher clinical response rate, lower VAS score, higher AOFAS score, higher MRI-defined bone marrow edema resolution rate (82.86% Conclusions: For PAN II, UG-MA-TP was associated with favorable mid-term (1-year) clinical and biomechanical outcomes compared with conventional therapy. It was associated with greater pain reduction, functional improvement, and tibialis posterior muscle tone regulation, with no recorded serious adverse events in this retrospective cohort. This treatment may be associated with favorable neuromuscular adaptations and may represent a minimally invasive option for selected patients with PAN II.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.